Simon Farrell 4

What Happened
Simon Farrell, Chief Commercial Officer of Trevi Therapeutics (TRVI), received a derivative award on February 19, 2026: an option covering 160,000 shares of common stock. The reported acquisition price is $0.00 (i.e., no cash was paid at grant); this is an option/award, not an immediate purchase or sale.

Key Details

• Transaction date: 2026-02-19 (filed with SEC on 2026-02-20).
• Transaction type/code: Award/Grant (derivative) — reported as "A".
• Shares/options granted: 160,000 underlying shares. Reported acquisition price: $0.00.
• Vesting: Per footnote, the 160,000 shares underlying the option vest in equal monthly installments through February 19, 2030, subject to continued service.
• Shares owned after transaction: Not specified in the filing.
• Timeliness: Filing appears timely (reported the next day); not marked as late.

Context
This was a standard equity award (option grant) to an executive — it gives the right to acquire shares in the future subject to vesting and service conditions. Such grants are common as long-term incentive compensation and do not represent an immediate market purchase or sale.